MSF responds to Pfizer and Medicines Patent Pool license for new Covid-19 treatment – “The deal, however, only covers 53 percent of the world’s population and excludes people in several upper-middle-income countries, leaving this promising medicine out of reach for millions”.
17 Nov, 2021 | 08:38h | UTC
Commentary on Twitter
Pfizer's deal w/ the Medicines Patent Pool for its COVID-19 treatment doesn't allow enough generic production & leaves this medicine out of reach for millions.
This is yet another restrictive voluntary license as cases continue to rise in many countries. https://t.co/WbVmUt9nrH
— Doctors w/o Borders (@MSF_USA) November 16, 2021